STOCK COMPARISON
Demant A/S vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Demant A/S (DEMANT) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Demant A/S trades at DKK 282 versus a fair value of DKK 161 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Demant A/S
DEMANT.CO · DKK · Health Care
-43%
upside to fair value
overvalued
PriceDKK 282
Fair ValueDKK 161
Quality59/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Demant A/SAbbott Laboratories
Valuation
24.4×P/E (TTM)27.7×
0.39×P/S (TTM)3.89×
0.90×P/B3.36×
5.1×EV/EBITDA15.1×
1.57×PEG1.47×
Profitability
7%Net margin14%
18%Operating margin13%
24%Return on equity12%
7%Return on assets6%
Growth
3%Revenue growth (YoY)8%
5.4%Avg. growth/yr (3Y)0.5%
9.8%Avg. growth/yr (5Y)5.1%
Balance & size
1.67×Debt / equity0.19×
$9BMarket cap$175B
healthyGrowth qualityhealthy
Demant A/S leads: 9 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Demant A/Sof which business quality 57 · market factors 70
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
49
50
Quality GrowthAre margins and returns improving?
11
47
CashflowEarnings quality: real cash, not paper profit
77
71
Fin. StrengthBalance sheet, leverage, solvency risk
35
80
InvestmentDisciplined investing over empire-building
75
65
Low VolatilityCalm price path (market factor)
69
83
MomentumPrice trend over the last 3–12 months (market factor)
70
40
52W MomentumDistance to the 52-week high (market factor)
72
33
Net IssuanceBuybacks instead of dilution
100
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Demant A/S
DCF ModelsDKK 207
Earnings-BasedDKK 80.90
Dividend DiscountDKK 4.84
MultiplesDKK 170
Asset-BasedDKK 31.27
Growth DCFDKK 212
Economic ProfitDKK 101
Growth EarningsDKK 148
24 of 26 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Demant A/S
Bear DKK 106Fair Value DKK 161Bull DKK 201
DKK 282 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Demant A/S · Health Care
Quality score59 · above median
Fair value upside-43% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Demant A/S trades at DKK 282 versus a fair value of DKK 161 (-43%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
